S5 Fig



S5 Fig. Inhibition of both CDK1 Kinase activity and lysosomal degradation increases the plasma membrane-associated enrichment of FGF receptors. (**A-B'**) Lateral sections and graphical summary of regional FGFR::VENUS enrichment for founder cells electroporated with *Mesp>FGFR::Venus* alone or in combination with *Mesp>HALO::Vam2*$^{421\text{-}841}$ and treated with vehicle (DMSO) or roscovitine (14μmol/L) as indicated. *Mesp>HALO::Vam2*$^{421\text{-}841}$ alone also resulted in a modest, but not significant, increase in plasma membrane-associated FGFR::VENUS. Because phalloidin staining obscures FGFR::VENUS localization, red dashed lines were used to indicate phalloidin stained cell membranes (**A-B**). Some regions are labeled with an a or b to denote significant changes ($p<0.05$) that occurred within this region across stages. Other regions are labeled n.s. to denote that no significant changes occurred for the indicated stages. Significance was determined using one-way ANOVA followed by Tukey's multiple comparison test. (**C**) Quantification of the FGFR::VENUS enrichment in the plasma membrane-associated region of founder cells electroporated and treated as indicated. Significance was determined using one-way ANOVA followed by Tukey's multiple comparison test. Numerical values for all graphs can be found in S10 Data. Scale bars are indicated in micrometers.